Primary care physicians may contribute to improved outcomes by recognizing the signs and symptoms early on. Part 2 of a Special Report.
For key facts and figures about musculoskeletal disorders, perhaps a surprise as the fourth leading diagnostic category in primary care, see the pages that follow.
What brings patients to your office—and not the specialty office down the street? Insights in this slideshow.
A new era in hepatitis C treatment began in May 2011, with approval of telaprevir and boceprevir. They are effective only for some patients, but new and better options are well on their way to the clinic.
Much like HIV/AIDS, RA is associated with a higher risk of cardiovascular disease and consequent death. How might inflammation add to the risk?
Joint deformity is far from the only concern in rheumatoid arthritis. The condition is associated with a variety of comorbidities and adverse events related to the medications used to prevent or treat symptoms, as these photos attest.
The location (pretibial surface) of this ulcer, its visibly rolled undermined border, and severe pain are all typical of pyoderma gangrenosum, which is typically associated with inflammatory bowel disease, rheumatoid arthritis, and hematologic malignancies.
Are persons with asthma at risk for other proinflammatory disorders? Yes, say researchers from the Mayo Clinic and Olmsted Medical Center in Rochester, Minn, who found that asthma is associated with the development of diabetes mellitus and coronary artery disease. However, there was no association between asthma and rheumatoid arthritis or inflammatory bowel disease.
More than half of patients with rheumatoid arthritis who were treated with a biologic discontinued treatment, and another 12% switched to at least 1 other biologic within a 2-year treatment period, according to a study led by Chureen Carter, PharmD, of Centocor Ortho Biotech Services.
As the number of biologic agents for rheumatoid arthritis (RA)—and rheumatologists’ use of these agents for RA and other rheumatological diseases—grows, getting coverage for RA treatment is taking an increasing investment of physicians’ staff time. However, the majority of respondents to a recent survey say it is an investment in patient care that is worth making.